'Game changer' prostate imaging agent granted FDA's Fast Track Designation
Health Imaging
AUGUST 25, 2024
The PET agent was developed for men with PSMA-positive lesions who have suspected metastasis and are candidates for initial definitive therapy.
Let's personalize your content